Introduction {#Sec1}
============

Coronaviruses (CoVs) are non-segmented positive-sense RNA viruses in the Coronaviridae family, Nidovirales order (Woo et al. [@CR39]; Cui et al. [@CR8]). These viruses characteristically contain crown-shaped peplomers of 80--160 nM size with 27--32 kb positive polarity (Woo et al. [@CR39]; Cui et al. [@CR8]). CoVs are pleomorphic and broadly distributed in mammals, especially humans. They have very high recombination rates. Therefore, they are constantly developing transcription errors and RNA-dependent RNA polymerase (RdRP) jumps (Woo et al. [@CR39]; Cui et al. [@CR8]).

CoVs have a high mutation rate (Cui et al. [@CR8]). Zoonotic pathogens (Peiris et al. [@CR28]) are present in humans and various animals and can cause clinical problems in the human respiratory, gastrointestinal, hepatic and neurologic systems with a wide range of asymptomatic strains that lead to hospitalization of patients in intensive care units (ICUs) (Cui et al. [@CR8]; Holshue et al. [@CR13]). CoVs used to be considered mild pathogens for humans and are the cause of the common cold (Peiris et al. [@CR28]), but they have gained more attention since being connected with severe acute respiratory syndrome (SARS) in China in 2002 and 2003 with mortality rates of 10% for SARS-CoV (Ksiazek et al. [@CR18]; Yin and Wunderink [@CR44]). The next of these outbreaks, and its control, occurred approximately 1 decade after SARS-CoV, when another highly pathogenic CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), emerged in Middle Eastern countries such as Saudi Arabia with a 37% mortality rate (Yin and Wunderink [@CR44]; Zaki et al. [@CR45]; Farooq et al. [@CR10]). Since December 8, 2019, a series of cases of pneumonia of of unknown etiologic origin emerged in Wuhan, Hubei province, China (Zhu et al. [@CR48]). This problem has been the focus of global attention because of clinical presentations, resembling viral epidemic pneumonia of unknown cause (Shen et al. [@CR31]; Chen et al. [@CR5]). Most patients worked at or lived near the local Huanan Seafood Wholesale Market, where livestock animals are traded (Zhu et al. [@CR48]; Shen et al. [@CR31]; Imai et al. [@CR15]).

First, an unknown pneumonia case was detected on December 12, 2019, by laboratory testing, and on January 1, 2020, the seafood market was closed (Zhu et al. [@CR48]). After this, on January 7, a novel coronavirus was identified by the Chinese Centers for Disease Control and Prevention (CDC) in a throat swab sample of a patient. This report was released by the Wall Street Journal, and the virus was subsequently named 2019-CoV by the World Health Organization (WHO) on January 9 (Tang et al. [@CR34]). The first viral genome sequence of 2019-nCoV was released online on January 10, one day after its formal approval, by Dr. Yong-Zhen Zhang and scientists at Fudan University, Shanghai (Wuhan-Hu-1, GenBank accession no. MN908947) (Wu et al. [@CR41]). On January 7, 2020, the Chinese higher-ups declared that a new type of coronavirus (novel coronavirus, nCoV) had been isolated (Read et al. [@CR30]). This virus changed to COVID-19 on February 11, 2020 (Phan [@CR29]). As of February 12 to March 1, 2020, 87,137 cases of COVID-19 had been reported and 2979 deaths (World Health Organization, 2019-nCoV Situation Report-41 on 01 [@CR40]). Although the source of COVID-19 is still unknown, after the first case developed (Phan [@CR29]; Li et al. [@CR20]), the infection was probably transmitted as a zoonotic agent (from animal to human) (Zhou et al. [@CR47]). The increase in the number of cases in China and internationally has indicated a second transmission from human to human (Phan [@CR29]; Gralinski and Menachery [@CR12]).

The geographic distribution of COVID-19 cases worldwide, as of March 1, 2020, is shown in Fig. [1](#Fig1){ref-type="fig"} (World Health Organization, 2019-nCoV Situation Report-41 on 01 [@CR40]). The daily increase in cases of COVID-19 and their distribution by continent (except China) as of March 1, 2020, are shown in Fig. [2](#Fig2){ref-type="fig"} (World Health Organization, 2019-nCoV Situation Report-41 on 01 [@CR40]). The number of cases of and deaths from COVID-19 is shown in Table [1](#Tab1){ref-type="table"} (World Health Organization, 2019-nCoV Situation Report-41 on 01 [@CR40]). Given the above statistics, the importance of the issue is clear. This study aimed to describe the methods to prevent and treat COVID-19 and provide an early evaluation of them.Fig. 1Geographic distribution of COVID-19 cases worldwide, as of March 1, 2020Fig. 2Distribution of COVID-19 cases by continent (except China), as of March 1, 2020Table 1The number of cases of and deaths from the COVID-19 outbreak according to World Health Organization (WHO) Situation Report-41 on March 1, 2020 (Woo et al. [@CR39])RegionsPlaces reporting casesConfirmed casesDeathsCommentsAsiaChina79,9682873Including 66,907 cases from Hubei PovinceAsiaRepublic of Korea360018AsiaIran59343AsiaJapan2395AsiaSingapore1020AsiaKuwait450AsiaThailand420AsiaBahrain410AsiaTaiwan400AsiaMalaysia250AsiaUnited Arab Emirates210AsiaVietnam160AsiaIraq130AsiaIsrael70AsiaOman60AsiaLebanon40AsiaPakistan40AsiaIndia30AsiaPhilippines31AsiaSri Lanka10AsiaAfghanistan10AsiaQatar10AsiaNepal10AsiaCambodia10EuropeItaly112829EuropeGermany1110EuropeFrance1002EuropeSpain660EuropeUK230EuropeSwitzerland180EuropeNorway150EuropeSweden130EuropeAustria100EuropeGreece70EuropeThe Netherlands70EuropeCroatia50EuropeFinland30EuropeGeorgia30EuropeDenmark30EuropeRomania30EuropeRussia20EuropeMonaco10EuropeAzerbaijan10EuropeNorth Macedonia10EuropeIreland10EuropeEstonia10EuropeIceland10EuropeLithuania10EuropeArmenia10EuropeBelarus10EuropeLuxembourg10EuropeBelgium10EuropeSan Marino10OtherCases on an international conveyance, Japan7056AmericaUSA691AmericaCanada200AmericaMexico40AmericaBrazil20AmericaEcuador10OceaniaAustralia261OceaniaNew Zealand10AfricaEgypt10AfricaNigeria10AfricaAlgeria10**Total87,1372979**

COVID-19 from SARS to MERS {#Sec2}
==========================

SARS-CoV, which originated in China and then spread to other parts of the world with hospital-acquired infectious cases, had a mortality rate of 10% and was transmitted to 8000 people during an 8-month outbreak in 2002--2003 (Ksiazek et al. [@CR18]; Yin and Wunderink [@CR44]; Luk et al. [@CR23]). In 2012, when MERS-CoV emerged in the Arabian Peninsula, it spread to 27 countries with a 35.6% mortality rate in 2220 cases (Yin and Wunderink [@CR44]; Zaki et al. [@CR45]; Farooq et al. [@CR10]). It is already known that both SARS and MERS are zoonotic viruses showing hospital-acquired and human-to-human transmission (Yin and Wunderink [@CR44]). Similar dynamics apply to this new strain named COVID-19 (CoVs), detected in Wuhan, Hubei Province, China, in December 2019, and the current rate of mortality is about 2% (Chen et al. [@CR5]; Huang et al. [@CR14]). It is also known that CoVs can use different receptors and pathways when entering the cell (Tortorici et al. [@CR36]).

While SARS-CoV usually infects the youngest (Luk et al. [@CR23]), MERS-CoV targets people aged \> 50 years (Yin and Wunderink [@CR44]), and COVID-19 infects middle-aged groups and above (Phan [@CR29]). Comparing non-respiratory complications, MERS-CoV involves the cardiovascular system more frequently than SARS-CoV and frequently requires vasopressor treatment (Cui et al. [@CR8]; Yin and Wunderink [@CR44]). On the other hand, some case reports have shown that COVID-19 affects the cardiovascular system (Lu et al. [@CR22]; Cao et al. [@CR3]). Acute kidney failure was more frequently observed in SARS-CoV and MERS-CoV epidemics compared with COVID-19 cases (Farooq et al. [@CR10]; Luk et al. [@CR23]). Whereas radiologic findings are present in all three pathogens, airspace opacifications are seen in SARS-CoV and a ground-glass appearance in MERS-CoV and COVID-19 (Yin and Wunderink [@CR44]; Jin et al. [@CR16]).

Hospital-acquired secondary infections have been described for all three pathogens (Cui et al. [@CR8]). Despite the knowledge about its etiology, no studies have reported a successful drug to treat the diagnosed patients (Wu et al. [@CR42]; Nguyen et al. [@CR25]). Regarding the epidemic periods, SARS-CoV has had the shortest reported epidemic period so far, ending less than a year after its outbreak (Luk et al. [@CR23]), and the MERS-CoV epidemic lasted for 7 years even though its spread was toward a more restricted area (Farooq et al. [@CR10]). The questions that follow are how long this novel COVID-19 strain outburst will last and what its impact on the world population will be, questions everyone is curious about.

Virus genome and structure {#Sec3}
==========================

CoVs are the best-known genome structure among all RNA viruses (Woo et al. [@CR39]). Two-thirds of their RNA has viral polymerase (RdRp), RNA synthesis materials and two large non-structural polyproteins that are not involved in host response modulation (ORF1a-ORF1b) (Jordan et al. [@CR17]). One-third of the genome encodes four structural proteins, spike (S), envelope (E), membrane (M) and nucleocapsid (N), as well as other helper proteins (Lu et al. [@CR22]; Paraskevis et al. [@CR26]). Even though the length of the CoV genome showed high variability for ORF1a/ORF1b and four structural proteins (Jordan et al. [@CR17]; Paraskevis et al. [@CR26]), it is mostly associated with the number and size of accessory proteins (Cui et al. [@CR8]; Tortorici et al. [@CR36]). The first step in virus infection was the interaction of sensitive human cells with S protein (Tortorici et al. [@CR36]; Cao et al. [@CR3]). Genome encoding occurs after entering the cell and facilitates the expression of the genes (Cui et al. [@CR8]), which encode useful accessory proteins (Tortorici et al. [@CR36]), and these advance the adaptation of CoVs to their human host (Lu et al. [@CR22]). Genome changes resulting from recombination, gene exchange, gene insertion or deletion have been frequent among CoVs, and this will take place in future outbreaks as well (Paraskevis et al. [@CR26]). The CoV subfamily is rapidly expanding with new generation sequencing applications that improve the detection and definition of novel CoV species (Read et al. [@CR30]). Briefly, CoV classification is continually changing. According to the most recent ranking of the International Committee on the Taxonomy of Viruses (ICTV), there are 4 genera of 38 unique species (Cui et al. [@CR8]).

Pathogenesis {#Sec4}
============

SARS-CoV and MERS-CoV attach to the host cell respectively bind to cellular receptor angiotensin-converting enzyme 2 (SARS-CoV associated) and cellular receptor of dipeptidyl peptidase 4 (MERS-CoV associated) (Tortorici et al. [@CR36]; Park et al. [@CR27]; Letko et al. [@CR19]). The viral RNA replicates in the cytoplasm after entering the cell (Letko et al. [@CR19]). Genomic RNA is encapsulated and polyadenylated, and it encodes various structural and non-structural polypeptide genes (Cui et al. [@CR8]; Subissi et al. [@CR33]). These polyproteins are split by proteases that exhibit chymotrypsin-like activity (Subissi et al. [@CR33]; Goo et al. [@CR11]). The resulting complex drives (−) RNA production through both replication and transcription (Jordan et al. [@CR17]). During replication, full-length (−) RNA copies of the genome are produced and used as a template for full-length (+) RNA genomes (Cui et al. [@CR8]; Jordan et al. [@CR17]). During transcription, a subset of 7--9 sub-genomic RNAs, including those encoding all structural proteins, are produced by discontinuous transcription (Cui et al. [@CR8]; Jordan et al. [@CR17]). Viral nucleocapsids are combined from genomic RNA and R protein in the cytoplasm and then are budded into the lumen of the endoplasmic reticulum (Cui et al. [@CR8]). Virions are then released from the infected cell through exocytosis (Cui et al. [@CR8]). The released viruses can infect kidney cells, liver cells, the intestines and T lymphocytes, as well as the lower respiratory tract, where they cause the main symptoms and signs. Remarkably, CDT lymphocytes were found to be \< 200 cells/mm3 in three patients with SARS-CoV infection (Cui et al. [@CR8]; Luk et al. [@CR23]; Paraskevis et al. [@CR26]). MERS-CoV can affect human dendritic cells, macrophages and T lymphocytes. This virus can make the antiviral T cell response irregular because of the stimulation of T cell apoptosis, thus causing a collapse of the immune system (Farooq et al. [@CR10]; Park et al. [@CR27]; Goo et al. [@CR11]; Cockrell et al. [@CR6]).

Epidemiology {#Sec5}
============

In December 2019, many pneumonia cases clustered in Wuhan were reported, and a search determined the source to be the Huanan seafood market (Chan et al. [@CR4]). The first patient of the COVID-19 epidemic was discovered with unexplained pneumonia on December 12, 2019, and 27 viral pneumonia cases, 7 severe, were officially made known on December 31, 2019 (Zhu et al. [@CR48]; Tang et al. [@CR34]). Etiologic investigations were made into patients who applied to the hospital for similar viral pneumonia findings (Chen et al. [@CR5]). The natural history of high-risk animal contact in the medical histories of these patients has strengthened the likelihood of an infection transmitted from animals to humans (Wu et al. [@CR41]; Zhou et al. [@CR47]). On January 22, 2020, novel CoVs were confirmed to originate from wild bats and belong to Group 2 of the beta-coronaviruses, which includes severe acute respiratory syndrome associated coronavirus (SARS-CoV) (Paraskevis et al. [@CR26]). Although COVID-19 and SARS-CoV belonged to the same beta coronavirus subgroup, genome-level similarities were only 70%, because the novel group has been found to show genetic differences from SARS-CoV (Lu et al. [@CR22]; Paraskevis et al. [@CR26]). The outbreak of the SARS epidemic and COVID-19 occurred during the Spring Festival in China (SFC), the country\'s most famous traditional festival, during which nearly 3 billion people travel countrywide (Chen et al. [@CR5]; Li et al. [@CR20]). These situations caused ideal conditions for the transmission of this highly contagious disease and severe difficulties in prevention and control of the epidemic (Read et al. [@CR30]). The SFC lasted from January 17 to February 23 in 2003, when the SARS epidemic peaked, and in 2020 January 10 to February 18 was the time of the SFC (Peiris et al. [@CR28]). Similarly, there was a quick increase in COVID-19 cases between January 10--22 (Read et al. [@CR30]).

Transmission {#Sec6}
============

CoVs have been defined as a novel respiratory tract virus in the samples collected from individuals who presented symptoms of respiratory tract infection in 1962 (Cui et al. [@CR8]). CoVs are a large family of viruses that are common in many different animal species, including camels, cattle, cats and bats (Cui et al. [@CR8]). Rarely, animal CoVs can infect humans and, as a result, may spread among humans during epidemics such as MERS, SARS and COVID-19 (Wu et al. [@CR41]). At the onset of significant outbreaks caused by CoVs, palm civets have been proposed to be a natural reservoir of human CoVs for SARS and dromedary camels for MERS (Cui et al. [@CR8]; Yin and Wunderink [@CR44]).

Conversely, more advanced virologic and genetic studies have shown that bats are reservoir hosts of both SARS-CoV and MERS-CoV (Yin and Wunderink [@CR44]), and before these viruses spread to humans (Cui et al. [@CR8]), they use the other animals as intermediate hosts. Studies have reported that most of the bat CoVs are the gene source of alpha-CoVs and beta-CoVs, whereas most of the bird CoVs are the gene source of gamma-CoVs and delta-CoVs (Zhou et al. [@CR47]). Recent studies have shown that the novel virus causing epidemics coincides with the CoV isolated in bats (Wu et al. [@CR41]; Zhou et al. [@CR47]; Drexler et al. [@CR9]). The presence of the wild animal trade in the Huanan seafood market, where the first cases appeared, supports this finding (Wu et al. [@CR41]; Zhou et al. [@CR47]).

After the first outbreak, secondary cases began to be reported after approximately 10 days (Wu et al. [@CR43]). Moreover, while these new patients had no contact with the marketplace, they had a history of contact with humans there (Wu et al. [@CR43]). Confirmed recent reports from many infected healthcare workers in Wuhan show that human-to-human transmission can occur (Chan et al. [@CR4]). As in SARS and MERS epidemics in the past, human-to-human transmission has accelerated the spread of the outbreak, and case reports have also started from other provinces in China (Luk et al. [@CR23]). The first non-Chinese case of the infection, which spread to the Chinese provinces, and then to the Asian continent, was reported from Thailand on January 13, 2020 (World Health Organization, 2019-nCoV Situation Report-41 on 01 [@CR40]). The patient reported being a Chinese tourist who had traveled to Thailand and had no epidemiologic connection with the marketplace (Li et al. [@CR20]). Other evidence from overseas countries such as the USA (Holshue et al. [@CR13]) and France has continued to be reported (Stoecklin et al. [@CR32]). This virus disseminated to the Midle Eastern region; for example, Iran was a region with potential to develop a major epidemiologic problem for healthcare (Zamani Ghaleshahi et al. [@CR46]; Tuite et al. [@CR37]). This virus has the potential to become a pandemic problem (MacIntyre [@CR24]).

Frequently, close contact leads to human-to-human transmission (Chan et al. [@CR4]). The transmission primarily occurs when an infected person sneezes and through the respiratory droplets produced, like in the spread of influenza and other respiratory pathogens (Chen et al. [@CR5]; Read et al. [@CR30]). These droplets can settle in the mouth or nasal mucosa and lungs of people with inhaled air (Li et al. [@CR20]). Currently, it remains unclear whether COVID-19 can infect a person by touching an infected surface or object and then touching their mouth, nose or possibly eyes (Chen et al. [@CR5]; Phan [@CR29]).

Typically, like most respiratory viruses, it is considered to be the most contagious when people are most symptomatic (Phan [@CR29]). However, patients who were infected by an asymptomatic person in the prodromal period of COVID-19 have also been reported (Jin et al. [@CR16]). Sufficient data are not available on the infectiousness of the disease, and research is ongoing.

Diagnosis {#Sec7}
=========

Before the cases of SARS-CoV, it was thought that human CoVs lead to a cold-like upper respiratory infection and self-limiting lower respiratory infection (Yin and Wunderink [@CR44]). The first death due to coronaviruses was reported by the isolation of SARS-CoV from a patient with pneumonia in China (Ksiazek et al. [@CR18]). As in other respiratory infection viruses and previous beta-CoVs, there are similarities in the clinical aspects of COVID-19 infections, and it is known that the clinical picture varies from simple respiratory infections to septic shock (Gralinski and Menachery [@CR12]). Similar to SARS-CoV and MERS-CoV, which have caused epidemics in the past years (Yin and Wunderink [@CR44]), the first symptoms are commonly fever, cough and shortness of breath (Huang et al. [@CR14]). Although diarrhea was present in about 20--25% of patients with MERS-CoV or SARS-CoV infection (Yin and Wunderink [@CR44]), intestinal symptoms have rarely been reported in patients with COVID-19 (Huang et al. [@CR14]). In another study, which included 99 patients, chest pain, confusion and nausea-vomiting were noted in addition to previous findings (Chen et al. [@CR5]). On x-rays or thorax CT imaging of the examined patients, unilateral or bilateral involvement compatible with viral pneumonia was found, and bilateral multiple lobular and sub-segmental consolidation areas were observed in patients hospitalized in the intensive care unit (Chen et al. [@CR5]; Huang et al. [@CR14]; Tang et al. [@CR35]).

In a cohort study that surveyed 41 hospitalized patients, fever, dry cough, myalgia and fatigue symptoms were reported in most patients; less often, symptoms of expectoration, headache, hemoptysis and diarrhea were also observed (Huang et al. [@CR14]). According to the study, comorbidities such as underlying diabetes mellitus, hypertension and cardiovascular disease were found in about half of these patients (Huang et al. [@CR14]). In addition, patients developed dyspnea accompanied by abnormal thorax CT compatible with pneumonia at mean 8 days after admission (Chen et al. [@CR5]). Complications include ARDS, acute heart damage, secondary infections and pneumothorax. Similar to the previous data, x-rays or thorax CT images of the patients revealed unilateral or bilateral lung involvement, compatible with viral pneumonia. Bilateral multiple lobular and sub-segmental consolidation areas were present in patients in the intensive care unit (Chen et al. [@CR5]; Gralinski and Menachery [@CR12]; Huang et al. [@CR14]; Jin et al. [@CR16]). The patients with underlying comorbidity exhibited a more severe clinical course, as expected from the experience gained from the previous epidemics (Jin et al. [@CR16]).

As in SARS and MERS, the diagnosis of 2019n-CoV infection is based on a history of detailed contact and travel and precise laboratory testing (Jin et al. [@CR16]). The diagnostic tools are molecular methods, serology and viral culture (Gralinski and Menachery [@CR12]; Jin et al. [@CR16]; Corman et al. [@CR7]). The most common diagnostic methods are molecular methods such as reverse transcription-polymerase chain reaction (RT-PCR) or real-time PCR, which are made using RNA from respiratory samples such as oropharyngeal swabs, sputum, nasopharyngeal aspirates, deep tracheal aspirates or broncho-alveolar lavage (Corman et al. [@CR7]). In particular, lower respiratory tract samples can offer a significantly higher viral load and genome fraction than upper respiratory tract samples. These techniques are beneficial in terms of evaluating the results quickly, showing the genome structure and viral load (Corman et al. [@CR7]).

The sensitivity of antibody detection is generally lower than that of molecular methods and is mostly used in retrospective diagnosis (Goo et al. [@CR11]; Li et al. [@CR21]). Viral culture is a more time-consuming method compared with the other methods. Culture is much more useful in the first stage of outbreaks before other diagnostic methods become clinically available. In addition, viral cultures can be used in the in-vitro and in-vivo antiviral treatment and vaccine evaluation trials (Jin et al. [@CR16]; Li et al. [@CR21]).

Prevention and treatment {#Sec8}
========================

In general, there are few or no treatment options for viral diseases of sudden occurrence (Nguyen et al. [@CR25]). Today, there is no vaccine or effective treatment to prevent COVID-19 infection (Nguyen et al. [@CR25]). Molecules are being tested for COVID-19 in in-vitro and human-based SARS-CoV, and MERS-Cov trials, and studies evaluating the antiviral activity of types I and II interferons have reported interferon-beta (IFNb) as the most potent interferon, which reduced in-vitro MERS-CoV replication (Nguyen et al. [@CR25]; Arabi et al. [@CR1]). According to a human MERS-CoV case report from South Korea, use of the combination of lopinavir/ritonavir (LPV/RTV) (anti-HIV drugs), pegylated interferon and ribavirin provided successful viral clearance (Arabi et al. [@CR1]). Another antiviral drug, remdesivir, was used in the first case reported in the USA, and it seemed successful; however, more cases are needed (Wang et al. [@CR38]). In-vitro studies have shown that viral RNA transcription was terminated with remdesivir in the early stages. Remdesivir showed strong antiviral activity in epithelial cell cultures against SARS-CoV, MERS-CoV and related zoonotic bat CoVs (Wu et al. [@CR42]; Wang et al. [@CR38]; Brown et al. [@CR2]).

In this early stage, dissemination of information is key, such as timely publication of epidemic statistics, early diagnosis, reporting, isolation and treatment. The CDC emphasizes necessary measures such as hand washing using disinfectant solutions and having minimal contact with patients to prevent the spread of the viral particles. Precautionary measures, including the provision of medicine supply chains, personal protection equipment and hospital supplies, should be carried out immediately not only for the protection of the Chinese people but also for the consequences for global health, especially in the places with travel ports close to major Chinese ports (Jin et al. [@CR16]).

Based on the 2003 SARS-CoV epidemic, the Chinese government carried out many effective measures, including limited access to public transportation, reducing migration flow and promoting personal protection providing masks to the inhabitants of Wuhan and other provinces. However, there are already reported cases of infected hospital personnel. Therefore, healthcare staff should be informed about and compelled to comply with any protective measures necessary, such as the use of gloves, eye masks and N95 masks when examining patients who could have been in contact with infected patients or have traveled to or been close to areas reporting cases of infection (China) (Phan [@CR29]; Li et al. [@CR20]; Jin et al. [@CR16]).

Future extension of COVID-19 {#Sec9}
============================

We need to consider the future course of COVID-19, which, as of February 12, 2020, had spread to 64 countries with 87,137 confirmed cases and 2979 deaths (Table [1](#Tab1){ref-type="table"}). With globalization, coronaviruses will spread, and there will be similar outbreaks of different mutant strains in the coming years. With increased international scientific collaboration, we may develop more powerful means of fighting coronaviruses, and we may understand the genome structure very well in the future. We have to be conscious of the challenges and worries 2019-nCoV has brought to our communities worldwide. Strenuous efforts should be made to learn about about and control the disease, and the time to act is now.
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